Literature DB >> 27025360

Prediction of bleeding and prophylactic platelet transfusions in cancer patients with thrombocytopenia.

Pernille J Vinholt1, Anne Alnor1, Mads Nybo1, Anne-Mette Hvas2.   

Abstract

Studies on markers for bleeding risk among thrombocytopenic cancer patients are lacking. This prospective observational cohort study investigated whether platelet parameters and a standardised bleeding questionnaire predicted bleeding or prophylactic platelet transfusions in patients with cancer and thrombocytopenia. Admitted adult patients with cancer and platelet count <80 × 10(9)/L were enrolled, but excluded if they experienced surgery or trauma within 7 days or platelet transfusion within 14 days. Patients were interviewed, blood samples collected and, subsequently, spontaneous bleeding and prophylactic platelet transfusion within 30 days were registered. Of 197 patients enrolled, 56 (28%) experienced bleeding. In multivariate analyses, predictors of bleeding were infection (adjusted odds ratio (OR) = 2.65 and 95% confidence interval (95% CI) 1.04-6.74); treatment with platelet inhibitors, heparin or warfarin OR = 2.34, 95% CI 1.23-4.48; urea nitrogen OR = 1.15, 95% CI 1.07-1.25; creatinine OR = 1.01, 95% CI 1.01-1.01; and haemoglobin OR = 0.62, 95% CI 0.41-0.93. Specific information regarding previous gastrointestinal bleeding OR = 3.33, 95% CI 1.19-9.34 and haematuria OR = 3.00, 95% CI 1.20-7.52 predicted bleeding whereas the standardised bleeding questionnaire did not. Prophylactic platelet transfusions were administered to 97 patients. Predictors of prophylactic platelet transfusions were: platelet count OR = 0.96, 95% CI 0.94-0.97; fibrinogen OR = 0.88, 95% CI 0.83-0.95; mean platelet volume OR = 0.69, 95% CI 0.49-0.97; platelet aggregometry with OR = 2.48, 95% CI 1.09-5.64 for collagen-induced platelet aggregation within the lowest quartile; and albumin OR = 1.07, 95% CI 1.01-1.15. In conclusion, except for immature platelet fraction (IPF), platelet parameters predicted prophylactic platelet transfusion but not bleeding. Bleeding risk factors were previous haematuria or gastrointestinal bleeding, infection, antiplatelet or anticoagulant treatment, high urea nitrogen, low haemoglobin or high creatinine.

Entities:  

Keywords:  Bleeding; bleeding questionnaire; platelet function; platelet transfusion; thrombocytopenia

Mesh:

Year:  2016        PMID: 27025360     DOI: 10.3109/09537104.2015.1131814

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  6 in total

Review 1.  Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.

Authors:  Roberto Castelli; Riccardo Schiavon; Valentina Rossi; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-04-19       Impact factor: 3.064

2.  Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism.

Authors:  Nathaniel R Wilson; Maliha Khan; Travis M Cox; Mohammed Nassif; Wei Qiao; Naveen Garg; Fleur M Aung; Thein Hlaing Oo; Cristhiam M Rojas-Hernandez
Journal:  EJHaem       Date:  2020-09-02

3.  EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.

Authors:  Anna Falanga; Avi Leader; Chiara Ambaglio; Zsuzsa Bagoly; Giancarlo Castaman; Ismail Elalamy; Ramon Lecumberri; Alexander Niessner; Ingrid Pabinger; Sebastian Szmit; Alice Trinchero; Hugo Ten Cate; Bianca Rocca
Journal:  Hemasphere       Date:  2022-07-13

4.  Big data modeling to predict platelet usage and minimize wastage in a tertiary care system.

Authors:  Leying Guan; Xiaoying Tian; Saurabh Gombar; Allison J Zemek; Gomathi Krishnan; Robert Scott; Balasubramanian Narasimhan; Robert J Tibshirani; Tho D Pham
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-09       Impact factor: 11.205

Review 5.  Platelets in aging and cancer-"double-edged sword".

Authors:  Alessandra V S Faria; Sheila S Andrade; Maikel P Peppelenbosch; Carmen V Ferreira-Halder; Gwenny M Fuhler
Journal:  Cancer Metastasis Rev       Date:  2020-09-01       Impact factor: 9.264

6.  Analysis of preplatelets and their barbell platelet derivatives by imaging flow cytometry.

Authors:  Samuel Kemble; Amanda Dalby; Gillian C Lowe; Phillip L R Nicolson; Steve P Watson; Yotis Senis; Steven G Thomas; Paul Harrison
Journal:  Blood Adv       Date:  2022-05-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.